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combination with insulin versus insulin alone for patients who are inadequately 
controlled despite high doses of insulin. Methods: The published and vali-
dated CARDIFF diabetes model was used to conduct the analysis. Clinical inputs 
were derived from a randomized clinical trial comparing dapagliflozin add-on to 
insulin with insulin regimens. Based on clinical inputs and the United Kingdom 
Prospective Diabetes Study (UKPDS) equations, the model predicts disease pro-
gression and the number of micro- and macro-vascular complications, along with 
diabetes-specific and all-cause mortality. The perspective of the National Health 
Service in England and Wales was adopted over a lifetime horizon. Local unit 
costs and utility data were assigned to the appropriate model parameters to cal-
culate total Quality-Adjusted-Life-Years (QALYs) and total costs. Univariate and 
probabilistic sensitivity analyses (PSA) were conducted. Results: Compared to 
insulin, dapagliflozin added to insulin was associated with 0.342 incremental 
QALYs (95%CI: 0.288; 0.480) at an additional cost of £1,813 (95%CI: £1,165; £2,381), 
resulting in an incremental cost-effectiveness ratio (ICER) point estimate of 
£5,295 per QALY gained. The univariate analyses showed that no input 
parameter change inflated the ICER above £15,000 per QALY. At a willingness-to-
pay threshold of £20,000 per QALY gained, the dapagliflozin treatment strategy 
was estimated to have a 100% probability of being cost-effective when compared 
to the insulin treatment strategy. These findings were shown to be robust with all 
sensitivity analyses. ConClusions: Dapagliflozin was shown to be a cost-effec-
tive treatment option in combination with insulin for patients who are inad-
equately controlled with insulin alone within established UK cost-effectiveness 
thresholds.
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objeCtives: To evaluate uncertainty, the NICE reference case requires estimation 
of cost-effectiveness using alternative parameter values. Because models of T2DM 
necessarily include many parameters, NICE requirements dictate a large number 
of simulations. This study assesses the relative importance of common sensitivity 
analyses by identifying key drivers of the incremental cost-effectiveness ratio (ICER) 
using the example of CANA 300mg versus GLIM (titrated from 1mg to 6mg or 8mg), 
in combination with metformin in dual therapy. Methods: The ECHO-T2DM model 
was used to simulate CANA versus GLIM over 40 years. ECHO-T2DM was loaded 
with patient characteristics, treatment effects, and adverse event rates from the 
DIA3009 trial. HbA1c was assumed to drift annually by 0.14% for CANA (similar to 
metformin in ADOPT), 0.24% for GLIM (as sulphonylurea in ADOPT), and 0.15% for 
rescue therapy with insulin (initiated when HbA1c > 7.5%). Twenty-four one-way 
sensitivity analyses assessed the impact of drug durability, macrovascular risk equa-
tions, utility weights, and HbA1c goals. Results: In the base case, CANA 300mg 
was associated with 0.21 greater QALYs at an incremental cost of £828, generating 
an ICER of £4,050/QALY. QALY gains were driven by fewer hypoglycaemic events 
and a better weight profile. The low acquisition cost of GLIM was partially offset by 
a greater need for insulin rescue therapy earlier in treatment, more hypoglycaemic 
events, and more macrovascular complications. Assuming no difference in durabil-
ity for CANA and GLIM had the greatest impact on the ICER (£49,717), followed by 
no disutility for hypoglycaemic events (£15,733). The only other scenario having a 
noticeable impact was an HbA1c goal of 9.0% (£9,718). Alternative macrovascular 
risk engines had little impact on the ICER. ConClusions: The ICER was robust 
under a large number of scenarios. Only the difference in assumed long-term GLIM 
durability reversed the interpretation of CANA as cost-effective versus GLIM using 
NICE criteria.
PDB60
sourCes of long-term QuAlity ADjusteD life yeAr (QAly) gAins for 
CAnAgliflozin (CAnA) versus glimePiriDe (glim) in the treAtment of 
tyPe 2 DiABetes mellitus (t2Dm) in the uK setting
Girod I.1, Willis M.2, Johansen P.2, Schroeder M.1, Thompson G.1, Neslusan C.3
1Janssen UK, High Wycombe, UK, 2The Swedish Institute for Health Economics, Lund, Sweden, 
3Janssen Global Services LLC, Raritan, NJ, USA
objeCtives: The NICE reference case for T2DM requires cost-utility analysis with a 
lifetime horizon. The denominator in cost-utility outcomes is the incremental QALY, 
which is driven in most T2DM economic models by several key features, including: 
life extension, micro- and macrovascular events, treatment and treatment-related 
adverse events (AEs), and excess bodyweight. This analysis aims to determine which 
factors most impact QALY gains using the example of CANA 300mg versus GLIM 
(titrated from 1mg to 6mg or 8mg) when combined with metformin. Methods: The 
ECHO-T2DM model was used to simulate CANA versus GLIM over 40 years. ECHO-
T2DM was loaded with patient characteristics, treatment effects, and AE rates from 
the DIA3009 trial. HbA1c was assumed to drift upwards at an annual rate of 0.14% 
for CANA (similar to metformin in the ADOPT trial) and 0.24% for GLIM (as sulpho-
nylurea in ADOPT). CANA and GLIM were discontinued and insulin initiated (annual 
drift 0.15% as in UKPDS) when patients failed to maintain HbA1c under 58 mmol/mol 
(7.5%). Results: Hypothetical patients experienced 0.21 more QALYs when treated 
with CANA 300mg versus GLIM. Because GLIM was associated with greater use of 
rescue medication (and extra insulin-mediated HbA1c lowering) in the simulation, 
HbA1c values converged asymptotically limiting the differences in microvascular 
complications. However, lower blood pressure for patients on CANA versus GLIM was 
associated with reductions of 2.2% to 4.1% for the rates of macrovascular outcomes 
(although associated QALY gains were small due to discounting). Differences in weight 
and especially hypoglycaemic events, related both to GLIM and to earlier initiation of 
insulin, were associated with improvements in utility (0.04 and 0.16 QALYs, respec-
vascular events, but substantial benefits attributable to weight (0.020) and especially 
hypoglycaemic events (0.024), related to CANA’s better weight-lowering and longer 
time to initiation of insulin. ConClusions: Patients treated with CANA in triple 
therapy experienced an additional 0.039 QALY’s over 40 years versus patients treated 
with SITA. The primary drivers were improved weight while on agent and fewer 
hypoglycaemic events.
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objeCtives: Dapagliflozin (Forxiga®) is the first sodium-glucose co-transporter-2 
(SGLT-2) inhibitor approved by the European Medicines Association, and positively 
assessed by the National Institute for Health and Care Excellence (NICE) for type 
2 diabetes mellitus. This study investigates the cost-effectiveness of dapagliflo-
zin compared with a sulphonylurea (SU) when added to metformin in patients 
inadequately controlled with metformin mono-therapy. Methods: The published 
and validated CARDIFF diabetes model was used to conduct the analysis. Clinical 
inputs were derived from a randomized clinical trial comparing dapagliflozin and 
glipizide in combination with metformin. Based on these clinical inputs and the 
United Kingdom Prospective Diabetes Study (UKPDS) equations, the model predicts 
disease progression and the number of micro- and macro-vascular complications, 
along with diabetes-specific and all-cause mortality. The perspective of the National 
Health Service in England and Wales was adopted over a lifetime horizon. Local 
unit costs and utility data were assigned to the appropriate model parameters to 
calculate total Quality-Adjusted-Life-Years (QALYs) and total costs. Univariate and 
probabilistic sensitivity analyses (PSA) were conducted. Results: Compared to 
SU added to metformin, dapagliflozin add-on to metformin was associated with 
an incremental benefit of 0.467 QALYs (95%CI: 0.420; 0.665) at an additional cost of 
£1,246 (95%CI: £613; £1,637), resulting in an ICER point estimate of £2,671 per QALY 
gained. The univariate analyses showed that no input parameter change inflated the 
ICER above £15,000 per QALY. The PSA showed that at a willingness-to-pay threshold 
of £20,000 per QALY gained, dapagliflozin treatment had an estimated 100% prob-
ability to be cost-effective compared to an SU treatment strategy. These findings 
were shown to be robust with all sensitivity analyses. ConClusions: Dapagliflozin 
in combination with metformin was shown to be a cost-effective treatment option 
for patients who are inadequately controlled with metformin mono-therapy within 
established UK cost-effectiveness thresholds.
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objeCtives: Insulin, often combined with metformin, is usually the last therapy 
option for patients with type 2 diabetes Mellitus (T2DM) who are uncontrolled on 
oral anti-diabetic drugs. Dutch guidelines recommend up-titration of insulin until 
patients maintain an HbA1c < 7%, yet in practice many patients never reach this tar-
get. Clinical evidence shows that dapagliflozin – a highly selective sodium-glucose 
cotransporter 2 (SGLT2) inhibitor – meets a need for these patients, i.e. by reduc-
ing HbA1c and weight. We studied the cost-effectiveness of dapagliflozin added to 
insulin (vs. not adding dapagliflozin) for patients with T2DM who have inadequate 
glycaemic control while on insulin. Methods: We used the Cardiff Diabetes model 
to evaluate cost and effects of dapagliflozin added to insulin using direct compara-
tive efficacy data from a randomized placebo-controlled trial (NCT00673231). In this 
trial up-titration of insulin was allowed in case of severe glycaemic imbalance. Risk 
factor progression and occurrence of future vascular events were estimated using 
the UKPDS 68 risk equations. Costs and utilities were derived from the literature. 
The analysis was conducted from a Dutch societal perspective using a lifetime hori-
zon. Results: The overall incidence of vascular complications was lower, and life 
expectancy was higher (19.43 LYs vs. 19.35 LYs) in those patients receiving dapagli-
flozin compared to patients not receiving dapagliflozin. Patients in the dapagliflozin 
arm obtained an incremental benefit of 0.42 QALYs. The lifetime incremental cost 
per patient in the dapagliflozin arm was € 2,293, resulting in an incremental cost-
effectiveness ratio of € 27,779 per LYG and an incremental cost-utility ratio of € 5,502 
per QALY gained. Sensitivity and scenario analyses showed that the results were 
robust to variation in modelling assumptions and input variables. ConClusions: 
This analysis shows that dapagliflozin increases the quality of life of T2DM patients 
compared to current practice (up-titration of insulin), and is cost-effective in a 
Dutch health care setting.
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objeCtives: Dapagliflozin (Forxiga®) is the first sodium-glucose co-transporter-2 
(SGLT-2) inhibitor approved by the European Medicines Association, and positively 
assessed by the National Institute for Health and Care Excellence (NICE) for type 2 
diabetes mellitus. This study assesses the costs-effectiveness of dapagliflozin in 
